Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Long-term benzodiazepines (BZDs) use is not endorsed in the treatment guidelines for anxiety disorders, but is prevalent in the real-world clinical settings. A systematic literature review was performed by using PubMed (last search: May 2019) to identify randomized controlled trials (RCTs) or maintenance studies following RCT that examined the effectiveness of BZDs in patients with anxiety disorders for a duration of 13 weeks or more. Meta-analyses were then conducted regarding changes in the Hamilton Anxiety Rating Scale (HAM-A) scores from baseline through endpoint, all-cause discontinuation, side effects, and the numbers of panic attacks at endpoint. Eight studies were identified (N = 1228). There were no significant differences in all outcomes between BZDs and antidepressants after the initial 8-week treatment. While no significant difference was noted in the HAM-A score changes between BZDs and placebo, BZDs resulted in a lower discontinuation rate and more frequent constipation and dry mouth than placebo. Our study indicates that for those who respond to an initial 8-week treatment, continuing BZDs is equivalent to antidepressants in efficacy and safety. However, the limited number of studies warranted further investigations of the long-term effectiveness and safety of BZDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Benzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676 · cited 2×
“Both psychological and pharmacological interventions play an integral part in the management of anxiety disorders (American Psychiatric Association, 1998; NICE, 2011; Baldwin et al., 2014; Katzman et al., 2014; Taylor et al., 2015).”
BackgroundBenzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
Hopewell, S., Dutton, S., Yu, L.-M., Chan, A.-W., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c723 · Cited by 504 · cited 1×
“These old studies might have been less rigorous and systematic in methodology from a viewpoint of current standard (Begg et al., 1996; Hopewell et al., 2010).”
BackgroundOffidani, E., Guidi, J., Tomba, E., & Fava, G. A. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000353198 · Cited by 166
Schweizer, E. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820130053009 · Cited by 120 · cited 1×
“Because the first study was a three-arm investigation, the data were extracted to compare either alprazolam or lorazepam with placebo, splitting the patients in the placebo group by half for each comparison (Senn, 2009).”
MethodUhlenhuth, E. H., Balter, M. B., Ban, T. A., & Yang, K. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199912002-00005 · Cited by 80
Nardi, A. E., Freire, R. C., Mochcovitch, M. D., Amrein, R., Levitan, M. N., King, A. L., Valença, A. M., Veras, A. B., Paes, F., Sardinha, A., et al. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823fe4bd · Cited by 56 · cited 7×
“(1993) to impute missing data, while the other studies adopted last-observation-carried forward analysis (Cohn and Wilcox, 1984; Curtis et al., 1993; Nardi et al., 2012).”
BackgroundMethodResultInfluentialInternational Task Force on Benzodiazepines
Balon, R., Chouinard, G., Cosci, F., Dubovsky, S. L., Fava, G. A., Freire, R. C., Greenblatt, D. J., Krystal, J. H., Nardi, A. E., Rickels, K., et al. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000489538 · Cited by 35
Cited by
Szuhany, K. L., & Simon, N. M. (2022) · JAMA · doi:10.1001/jama.2022.22744 · Cited by 541
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
Benzodiazepines Remain Important Therapeutic Options in Psychiatric Practice
Dubovsky, S. L., & Marshall, D. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524400 · Cited by 171
Metadata
- Authors
- Shinfuku, M., Kishimoto, T., Uchida, H., Suzuki, T., Mimura, M., & Kikuchi, T.
- Venue
- International Clinical Psychopharmacology
- Published
- 2019-09
- Volume
- 34
- Issue
- 5
- Pages
- 211-221
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2957405451
- Cited by
- 45
- References
- 11
- FWCI
- 5.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1097/yic.0000000000000276
- The paper
- Shinfuku, M., Kishimoto, T., Uchida, H., Suzuki, T., Mimura, M., & Kikuchi, T. (2019). Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000276
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.